세계의 반려동물 의약품 시장 보고서(2025년)
Companion Animal Pharmaceuticals Global Market Report 2025
상품코드 : 1793367
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

반려동물 의약품 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 10.2%를 나타내 263억 4,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 반려동물을위한 맞춤형 의료, 원격 의료 및 원격 수의학 서비스, 영양 및 영양 보조 식품에 대한 주력, 건강 이니셔티브 및 수의 진단 서비스의 확대로 인한 것입니다. 예측기간의 주요 동향으로는 동물의료 진보, 노화하는 반려동물에 특화된 치료법, 규제 준수 및 안전 기준, 공동 연구 및 파트너십 등이 있습니다.

향후 5년간의 성장률 10.2%라고 하는 예측은 전회의 예측으로부터 0.1%의 미감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 영국이나 캐나다에서 출하된 완성 동물용 의약품에 대한 과징금은 가격 경쟁을 약화시키고 제네릭 의약품의 이용 가능성을 저하시킵니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

인수 공통 감염의 이환율 상승은 반려동물 의약품 시장 성장을 이끌 것으로 예측됩니다. 인간 짐승 공통 감염은 척추동물과 인간 사이에 감염될 수 있으며 공중 보건에 큰 도전이 되고 있습니다. 이에 대해 제약 업계는 이러한 질병과 싸우고 감염 위험을 줄이기 위해 건강 원칙에 따른 최신 전략을 전개하고 있습니다. 2022년 12월 유럽 질병 예방관리센터의 보고서에서는 캄필로박테리움증을 비롯한 인류 공통 감염의 확산이 확대되고 있음을 강조하고 의약품에 의한 개입의 필요성을 강조했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Companion animal pharmaceuticals involve the pharmaceutical medication process where animal pharmacists recommend medications, fill prescriptions, and manage drug therapies for animals. It is utilized in the diagnosis, mitigation, and treatment of various diseases in animals.

The main types of companion animal pharmaceuticals include medications for dogs, cats, horses, and other companion animals. Dogs are highly variable carnivorous domesticated mammals closely related to the common wolf. The indications for these pharmaceuticals cover infectious diseases, dermatologic diseases, pain management, orthopedic diseases, behavioral issues, and other conditions. These medications are typically sold through various distribution channels such as veterinary hospitals, veterinary clinics, and retail pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The rapid escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a considerable impact on the veterinary healthcare sector, particularly in the supply of pharmaceuticals, medical devices, and animal care products. Increased duties on imported veterinary medicines, diagnostic equipment, surgical tools, and pet care supplies have driven up operational costs for veterinary clinics, animal hospitals, and livestock health providers, forcing them to either raise service charges or absorb reduced profit margins. The livestock and agricultural industries are facing similar pressures, as tariffs on feed additives, vaccines, and breeding equipment push up production costs and complicate animal health management. Furthermore, retaliatory tariffs in major export markets have weakened demand for U.S.-manufactured veterinary products, adding to revenue challenges. To navigate these headwinds, the sector must now focus on local sourcing, preventive healthcare strategies, and digital veterinary solutions to control costs while continuing to deliver quality animal care.

The companion animal pharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides companion animal pharmaceuticals market statistics, including companion animal pharmaceuticals industry global market size, regional shares, competitors with a companion animal pharmaceuticals market share, detailed companion animal pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the companion animal pharmaceuticals industry. This companion animal pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The companion animal pharmaceuticals market size has grown strongly in recent years. It will grow from $16.49 billion in 2024 to $17.85 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to humanization of pets, preventive healthcare measures, rise in pet insurance, changing lifestyle and urbanization, zoonotic disease concerns, zoonotic disease concerns, veterinary healthcare accessibility.

The companion animal pharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $26.34 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to personalized medicine for pets, telehealth and remote veterinary services, focus on nutrition and nutraceuticals, one health initiatives, expansion of veterinary diagnostic services. Major trends in the forecast period include advancements in veterinary medicine, specialized therapeutics for aging pets, regulatory compliance and safety standards, collaborations and partnerships.

The forecast of 10.2% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Levies on finished veterinary drugs shipped from the UK and Canada will dampen price competition and reduce generic availability. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of zoonotic diseases is anticipated to drive growth in the companion animal pharmaceuticals market. Zoonotic illnesses, capable of transmission between vertebrate animals and humans, present a considerable public health challenge. In response, the pharmaceutical industry is deploying modern strategies aligned with health principles to combat these diseases and reduce transmission risks. A December 2022 report by the European Centre for Disease Prevention and Control underscores the increasing prevalence of Campylobacteriosis and other zoonotic diseases, highlighting the need for pharmaceutical interventions.

The companion animal pharmaceutical market is poised for growth, fueled by an upsurge in pet ownership. Pet ownership, signifying the human assumption of responsibility for animal care, is on the rise. The market benefits from an expanding pet owner base and a growing recognition of the importance of preventive measures, diagnostics, and treatments for companion animal health. A report from the American Veterinary Medical Association in October 2022 reveals a substantial increase in families owning at least one cat. The trend, supported by increased veterinary spending, underscores the market's growth potential.

The adoption of big data technologies is a noteworthy trend in the companion animal pharmaceuticals sector. Leading companies are actively developing technological solutions to fortify their market positions. Notably, Elanco Animal Health Incorporated and Ginkgo Bioworks launched BiomEdit in April 2022. This microbiome innovation company focuses on developing novel probiotics and related animal pharmaceuticals. The initiative extends to areas such as medicated feed ingredients, nutritional health, therapies for livestock and pets, and biosecurity technologies for monitoring animal illnesses.

Major companies in the companion animal pharmaceutical market are introducing innovative products, such as oral flea and tick treatments, to expand their customer bases, boost sales, and enhance revenue. Oral flea and tick products are medications administered orally to prevent or treat infestations in pets. For example, in October 2024, Elanco Animal Health Incorporated, a US-based pharmaceutical firm, received FDA approval for Credelio Quattro, a new chewable parasiticide formulated for dogs. This product provides monthly protection against six types of parasites, including fleas, ticks, and various internal worms. With the launch of Credelio Quattro, Elanco aims to offer a convenient, comprehensive solution for pet owners seeking broad-spectrum parasite control. This introduction underscores Elanco's commitment to addressing the rising demand for innovative and effective pet health solutions.

In July 2022, Dechra Pharmaceuticals completed the acquisition of Piedmont Animal Health for $210 million. This strategic move enhances Dechra's product portfolio for European and North American markets and augments its scientific and regulatory capabilities. Piedmont Animal Health, a US-based company specializing in companion animal pharmaceuticals, brings complementary offerings to further strengthen Dechra's position in the industry.

Major companies operating in the companion animal pharmaceuticals market are Elanco Animal Health Incorporated, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Chanelle Pharma, Eco Animal Health Group PLC, Ashish Life Science Pvt. Ltd., Endovac Animal Health, Hipra Laboratories, Indian Immunologicals Ltd., Inovet Group, Kyoritsu Seiyaku Corporation, Lutim Pharma Pvt. Ltd., Merck & Co. Inc., Norbrook Laboratories Ltd., Tianjin Ringpu Bio-Technology Co. Ltd., Vetoquinol S.A., Virbac S.A., Zoetis Inc., Agrolabo S.p.A., ALS Pvt. Ltd., Zydus Animal Health and Investments Limited, Eli Lilly and Company, IDEXX Laboratories Inc., Merial Limited, Novartis Animal Health Inc., Dechra Pharmaceuticals PLC, Aratana Therapeutics Inc., Phibro Animal Health Corporation, Kindred Biosciences Inc., Jaguar Health Inc., Nexvet Biopharma PLC, Sentinel Biomedical Inc., PetMed Express Inc., Neogen Corporation, Heska Corporation, Synbiotics Corporation, Eurovet Animal Health B.V., Vironova AB, Abaxis Inc., Bioiberica S.A.U., Putney Inc., Lohmann Animal Health International

North America was the largest region in the companion animal pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the companion animal pharmaceuticals market report during the forecast period. The regions covered in the companion animal pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the companion animal pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The companion animal pharmaceuticals market includes revenues earned by entities by providing veterinary pharmaceuticals, vaccines, and health management tools. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Companion Animal Pharmaceuticals Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on companion animal pharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for companion animal pharmaceuticals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The companion animal pharmaceuticals market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Companion Animal Pharmaceuticals Market Characteristics

3. Companion Animal Pharmaceuticals Market Trends And Strategies

4. Companion Animal Pharmaceuticals Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Companion Animal Pharmaceuticals Growth Analysis And Strategic Analysis Framework

6. Companion Animal Pharmaceuticals Market Segmentation

7. Companion Animal Pharmaceuticals Market Regional And Country Analysis

8. Asia-Pacific Companion Animal Pharmaceuticals Market

9. China Companion Animal Pharmaceuticals Market

10. India Companion Animal Pharmaceuticals Market

11. Japan Companion Animal Pharmaceuticals Market

12. Australia Companion Animal Pharmaceuticals Market

13. Indonesia Companion Animal Pharmaceuticals Market

14. South Korea Companion Animal Pharmaceuticals Market

15. Western Europe Companion Animal Pharmaceuticals Market

16. UK Companion Animal Pharmaceuticals Market

17. Germany Companion Animal Pharmaceuticals Market

18. France Companion Animal Pharmaceuticals Market

19. Italy Companion Animal Pharmaceuticals Market

20. Spain Companion Animal Pharmaceuticals Market

21. Eastern Europe Companion Animal Pharmaceuticals Market

22. Russia Companion Animal Pharmaceuticals Market

23. North America Companion Animal Pharmaceuticals Market

24. USA Companion Animal Pharmaceuticals Market

25. Canada Companion Animal Pharmaceuticals Market

26. South America Companion Animal Pharmaceuticals Market

27. Brazil Companion Animal Pharmaceuticals Market

28. Middle East Companion Animal Pharmaceuticals Market

29. Africa Companion Animal Pharmaceuticals Market

30. Companion Animal Pharmaceuticals Market Competitive Landscape And Company Profiles

31. Companion Animal Pharmaceuticals Market Other Major And Innovative Companies

32. Global Companion Animal Pharmaceuticals Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Companion Animal Pharmaceuticals Market

34. Recent Developments In The Companion Animal Pharmaceuticals Market

35. Companion Animal Pharmaceuticals Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기